MEMPHIS, TN
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)ST JUDE CHILDREN'S RESEARCH HOSPITAL INC, founded in 1959, is a large national nonprofit in the Health Care sector that reported $2.2B in total revenue in fiscal year 2024. Revenue grew 10% year-over-year, indicating healthy expansion. Expenses of $1.9B left a modest 14% surplus.
THE MISSION OF ST. JUDE CHILDREN'S RESEARCH HOSPITAL IS TO ADVANCE CURES, AND MEANS OF PREVENTION, FOR PEDIATRIC CATASTROPHIC DISEASES THROUGH RESEARCH AND TREATMENT. CONSISTENT WITH THE VISION OF OUR FOUNDER DANNY THOMAS, NO CHILD IS DENIED (CONTINUED ON SCHEDULE O) TREATMENT BASED ON RACE, RELIGION OR A FAMILY'S ABILITY TO PAY.
RESEARCH: THE CURRENT BASIC SCIENCE AND CLINICAL RESEARCH AT THE HOSPITAL INCLUDES WORK IN GENE THERAPY, CHEMOTHERAPY, THE BIOCHEMISTRY OF NORMAL AND CANCEROUS CELLS, RADIATION TREATMENT, BLOOD...
RESEARCH: THE CURRENT BASIC SCIENCE AND CLINICAL RESEARCH AT THE HOSPITAL INCLUDES WORK IN GENE THERAPY, CHEMOTHERAPY, THE BIOCHEMISTRY OF NORMAL AND CANCEROUS CELLS, RADIATION TREATMENT, BLOOD DISEASES, RESISTANCE TO THERAPY, VIRUSES, NEUROLOGICAL DISEASES, HEREDITARY DISEASES, INFLUENZA, PEDIATRIC AIDS AND PHYSIOLOGICAL EFFECTS OF CATASTROPHIC ILLNESSES.
PATIENT CARE: THE HOSPITAL PROVIDED 17,927 INPATIENT DAYS OF CARE DURING THE YEAR. OUR BONE MARROW TRANSPLANTATION PROGRAM ACCOUNTED FOR 3,805 OR 21% OF THOSE INPATIENT DAYS. PATIENTS MADE 74,651...
PATIENT CARE: THE HOSPITAL PROVIDED 17,927 INPATIENT DAYS OF CARE DURING THE YEAR. OUR BONE MARROW TRANSPLANTATION PROGRAM ACCOUNTED FOR 3,805 OR 21% OF THOSE INPATIENT DAYS. PATIENTS MADE 74,651 CLINIC REGISTRATIONS DURING THE YEAR.
EDUCATION AND TRAINING: AS PART OF ITS MISSION, THE INSTITUTION HAS DEVELOPED A GLOBAL INITIATIVE (ST. JUDE GLOBAL) TO IMPROVE THE SURVIVAL RATES OF CHILDREN WITH CANCER AND OTHER CATASTROPHIC...
EDUCATION AND TRAINING: AS PART OF ITS MISSION, THE INSTITUTION HAS DEVELOPED A GLOBAL INITIATIVE (ST. JUDE GLOBAL) TO IMPROVE THE SURVIVAL RATES OF CHILDREN WITH CANCER AND OTHER CATASTROPHIC DISEASES WORLDWIDE. ST. JUDE GLOBAL ACCOMPLISHES THIS BY SHARING KNOWLEDGE, TECHNOLOGY AND ORGANIZATIONAL SKILLS, HELPING TO IMPLEMENT NEW APPROACHES TO TREAT PEDIATRIC CANCER GLOBALLY, AND DEVELOPING REGIONAL NETWORKS COMMITTED TO ERADICATING CANCER IN CHILDREN. THIS MISSION WILL BE ACHIEVED BY FOCUSING ON THREE OVERRIDING GOALS: (1) TO TRAIN THE CLINICAL WORKFORCE THAT WILL BE REQUIRED TO MEET OUR MISSION, (2) TO DEVELOP AND STRENGTHEN HEALTH SYSTEMS AND PATIENT-CENTERED INITIATIVES THAT ENCOMPASS THE ENTIRE CONTINUUM OF CARE REQUIRED FOR CHILDREN WITH CANCER AND NON-MALIGNANT HEMATOLOGICAL (CONTINUED ON SCHEDULE O) DISEASES, AND (3) TO ADVANCE KNOWLEDGE IN GLOBAL PEDIATRIC ONCOLOGY AND HEMATOLOGY THROUGH RESEARCH TO SUSTAIN A CONTINUOUS IMPROVEMENT IN THE LEVEL AND QUALITY OF CARE DELIVERED AROUND THE GLOBE. THESE INITIATIVES ARE SPEARHEADED BY ST. JUDE EXPERTS WHO WORK CLOSELY WITH HEALTHCARE PROFESSIONALS AT OUR PARTNER SITES.THE GLOBAL INITIATIVE FOR CHILDHOOD CANCER, LAUNCHED IN 2018 BY ST. JUDE IN PARTNERSHIP WITH WHO AND GLOBAL COLLABORATORS, AIMS TO ADDRESS DISPARITIES IN CHILDHOOD CANCER OUTCOMESWHERE SURVIVAL IS BELOW 30% IN MANY LOW AND MIDDLE INCOME COUNTRIES COMPARED TO OVER 80% IN HIGH INCOME SETTINGS. THE INITIATIVE SEEKS TO RAISE GLOBAL SURVIVAL TO AT LEAST 60% BY 2030 BY STRENGTHENING COUNTRIES' ABILITY TO DELIVER QUALITY CANCER CARE AND ELEVATING CHILDHOOD CANCER AS A NATIONAL AND INTERNATIONAL HEALTH PRIORITY. STAKEHOLDERS ACROSS SECTORS ARE WORKING TOGETHER TO IMPROVE ACCESS, CAPACITY, AND COORDINATED ACTION FOR CHILDREN WITH CANCER WORLDWIDE.THE GLOBAL PLATFORM FOR ACCESS TO CHILDHOOD CANCER MEDICINES IS A MAJOR EFFORT LED BY ST. JUDE TO ENSURE LIFESAVING CANCER TREATMENTS ARE AVAILABLE, ACCESSIBLE, AFFORDABLE, AND HIGH QUALITY FOR CHILDREN WORLDWIDE. BACKED BY A $200 MILLION ST. JUDE INVESTMENT AND BUILT IN PARTNERSHIP WITH WHO, UNICEF, AND PAHO, THE INITIATIVE IS RESTRUCTURING THE FRAGMENTED PEDIATRIC CANCER MEDICINE MARKET TO HELP ACHIEVE GLOBAL SURVIVAL GOALS. PILOT DELIVERIES BEGAN IN 2025, WITH ADDITIONAL COUNTRIES NOW ONBOARDING AS THE PROGRAM SCALES TOWARD REACHING 120,000 CHILDREN WITHIN THE NEXT SEVEN YEARS.GRADUATE PROGRAMS AT BOTH THE MASTER'S AND DOCTORAL LEVELS ARE OFFERED THROUGH A WHOLLY OWNED SUBSIDIARY, ST. JUDE CHILDREN'S RESEARCH HOSPITAL GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, LLC, TO EDUCATE THE NEXT GENERATION OF BIOMEDICAL RESEARCHERS TO PROBE THE MOLECULAR BASIS OF DISEASE, DEVELOP NOVEL THERAPIES AND TRAIN MEDICAL PROFESSIONALS TO ADVANCE GLOBAL HEALTH FOR CHILDREN WITH CATASTROPHIC DISEASES.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $2,208,853,162 | $2,009,853,917 | +0.1% |
| Expenses | $1,897,571,834 | $1,772,678,423 | +0.1% |
| Net Income | $311,281,328 | $237,175,494 | +0.3% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| JAMES R DOWNING | PRESIDENT/CEO | 55.00 |
Officer
Director
|
$1,647,264 | $66,619 | $1,713,883 |
| RICHARD C SHADYAC JR | EX-OFFICIO DIRECTOR (THRU 3/25) | 1.00 |
Director
|
$0 | $171,359 | $1,564,611 |
| JOYCE A ABOUSSIE | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| STEVEN J ALLEN MD | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| JOSEPH S AYOUB JR ESQ | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| PAUL J AYOUB ESQ | VOTING DIRECTOR | 8.00 |
Director
|
$0 | $0 | $0 |
| FREDERICK M AZAR MD | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| KHALIL Z BARRAGE | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| MARTHA PERINE BEARD | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| TERRY L BURMAN | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| LISA R DILLER MD | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| JOSEPH E EID MD | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| JOHN D FARINA | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| FRED P GATTAS III PHARMD | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| GABRIEL G HADDAD MD | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| JUDY A HABIB | VOTING DIRECTOR | 8.00 |
Director
|
$0 | $0 | $0 |
| CHARLES C HAJJAR | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| FOUAD A HAJJAR MD | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| MICHAEL K HAMRA | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| FREDERICK R HARRIS JR MD | VOTING DIRECTOR | 8.00 |
Director
|
$0 | $0 | $0 |
| CARLA Z HASSAN | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| J DAVID KARAM II | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| SCOTT A KUPOR | VOTING DIRECTOR (THRU 4/25) | 4.00 |
Director
|
$0 | $0 | $0 |
| KATHERINE N LAPP | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| SHARON L MCCOLLAM | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| SAMIA MELHEM | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| ROBERT T MOLINET ESQ | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| NEELA M MONTGOMERY | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| RAMZI N NUWAYHID | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| THOMAS J PENN III | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| CHRISTINA M RASHID | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| KATHRYNE G REEVES | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| CAMILLE F SARROUF JR ESQ | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| AARTI S SHAH | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| JOSEPH G SHAKER | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| GEORGE A SIMON II | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| MICHAEL C SIMON | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| TONY THOMAS | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| TAMA H ZAYDON | VOTING DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| JOSEPH P TAYLOR | EVP/SCIENTIFIC DIRECTOR | 55.00 |
Officer
|
$1,400,509 | $157,805 | $1,558,314 |
| CHARLES M ROBERTS | EVP/DIRECTOR CANCER CENTER | 55.00 |
Officer
|
$1,133,977 | $131,966 | $1,265,943 |
| CARLOS RODRIGUEZ-GALINDO | EVP/CHAIR | 55.00 |
Officer
|
$1,044,495 | $122,770 | $1,167,265 |
| ELLIS NEUFELD | EVP/CLINICAL DIRECTOR | 55.00 |
Officer
|
$1,061,163 | $69,119 | $1,130,282 |
| ROBYN DIAZ | EVP/CHIEF LEGAL OFFICER | 55.00 |
Officer
|
$792,603 | $142,796 | $935,399 |
| PATRICIA A KEEL | EVP/CHIEF FINANCIAL OFFICER | 55.00 |
Officer
|
$860,796 | $63,375 | $924,171 |
| MARIA MEGDAL | EVP/CHIEF ADMINISTRATIVE OFFICER | 55.00 |
Officer
|
$269,932 | $1,128 | $271,060 |
| THOMAS E MERCHANT | CHAIR | 55.00 |
Highest
|
$1,143,949 | $78,286 | $1,222,235 |
| ANDREW DAVIDOFF | CHAIR | 55.00 |
Highest
|
$1,059,112 | $66,560 | $1,125,672 |
| MADAN MOHAN | CHAIR | 55.00 |
Highest
|
$980,114 | $93,227 | $1,073,341 |
| DAVID ELLISON | CHAIR | 55.00 |
Highest
|
$940,893 | $50,642 | $991,535 |
| MICHAEL DYER | CHAIR | 55.00 |
Highest
|
$892,206 | $75,236 | $967,442 |
| JAMES I MORGAN | FORMER OFFICER | 55.00 |
|
$559,972 | $69,408 | $629,380 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $2,208,853,162 | $1,897,571,834 | $12,933,669,993 | $311,281,328 |
| 2024 | No data | No data | No data | No data |
| 2023 | $1,707,244,071 | $1,519,049,173 | $10,479,499,175 | $188,194,898 |
| 2022 | $1,385,684,376 | $1,278,569,778 | $9,470,257,087 | $107,114,598 |
| 2021 | $1,272,197,039 | $1,166,556,148 | $9,161,722,368 | $105,640,891 |
| 2020 | $1,238,182,174 | $1,103,980,537 | $6,740,895,238 | $134,201,637 |
| 2019 | $1,107,969,131 | $1,021,442,301 | $6,214,238,431 | $86,526,830 |
| 2018 | $980,656,319 | $950,715,632 | $5,434,170,902 | $29,940,687 |
Compare ST JUDE CHILDREN'S RESEARCH HOSPITAL INC with other nonprofits in Tennessee and across the country.